In January 2025, the Society for Women’s Health Research (SWHR) released its inaugural Women’s Health Research Agenda, a groundbreaking strategic roadmap that prioritizes uterine health—with a special emphasis on uterine fibroids—alongside autoimmune disease and cardiometabolic health. Published in the Journal of Women’s Health, this SWHR fibroids 2025 initiative highlights the need for expanded research, funding, and equitable care for conditions like fibroids, which affect up to 80% of women by age 50 and disproportionately impact Black women. As part of trending fibroid advocacy in 2025, including legislative packages for dedicated fibroid research dollars, the agenda positions minimally invasive treatments like Uterine Fibroid Embolization (UFE) as key solutions for improving outcomes. At Surgical Associates, we align our Women’s Health services with this uterine health research, offering UFE as an effective, uterus-preserving option for women in Maryland, DC, and Virginia.
Led by board-certified interventional radiologist Dr. Albert Chun, our team at sacmd.com integrates SWHR’s insights to provide patient-centered care amid these research advancements. Whether you’re dealing with heavy bleeding, pain, or fertility concerns from fibroids, understanding this agenda can guide your treatment choices. Schedule a screening or consultation at our Camp Springs, Waldorf, Washington D.C., Silver Spring, or Reston locations today. Call (240) 427-1630 or visit www.sacmd.com. Your journey to be Fibroid Free with UFE starts here!
Overview of SWHR’s 2025 Women’s Health Research Agenda
The SWHR 2025 Agenda, introduced in celebration of the organization’s 35th anniversary, serves as a call to action for stakeholders to address critical gaps in women’s health research. It outlines priorities in three key areas: uterine health (focusing on uterine fibroids), autoimmune disease (with emphasis on lupus), and cardiometabolic health (highlighting metabolism in women). As detailed in the Journal of Women’s Health publication, the agenda aims to foster collaboration, drive innovation, and promote equity in research and care.
SWHR’s focus stems from the recognition that conditions like fibroids receive insufficient attention despite their widespread impact, including heavy menstrual bleeding, pelvic pain, and fertility challenges. The agenda builds on 2025 advocacy efforts, such as legislative packages introduced in July to expand fibroid research funding and coordinate federal programs. This aligns with broader trending fibroid advocacy, including World Health Day recognitions and social media campaigns emphasizing uterine health research.
At Surgical Associates, we support this agenda by offering treatments like UFE that address fibroids’ core issues without invasive surgery. Explore our Vascular Surgery services to see how we apply these priorities in Maryland, DC, and Virginia.
Prioritizing Uterine Fibroids: SWHR’s Key Focus
Uterine fibroids take center stage in SWHR’s uterine health priority, described as non-cancerous tumors that can cause significant morbidity, including chronic pain, heavy bleeding, and reproductive complications. The agenda calls for intensified research to understand fibroids’ causes, improve diagnostics, and develop innovative treatments, particularly for underserved populations like Black women who experience earlier onset and more severe symptoms.
SWHR advocates for multidisciplinary approaches, including minimally invasive options that preserve fertility and quality of life. This directly ties to UFE, a procedure that shrinks fibroids by blocking their blood supply, offering 85-90% symptom relief with minimal downtime. In the context of SWHR fibroids 2025, UFE emerges as a key solution for addressing research gaps in equitable, effective care.
Dr. Albert Chun at Surgical Associates uses these insights to tailor UFE for patients, ensuring alignment with SWHR’s emphasis on reducing disparities and improving outcomes.
Visit our About Us page to learn how we contribute to trending fibroid advocacy.
Positioning UFE as a Key Solution in SWHR’s Agenda
SWHR’s agenda promotes treatments that go beyond traditional surgery, highlighting the need for options like UFE that are less invasive and fertility-preserving. UFE directly supports the agenda’s goals by providing a safe, outpatient procedure with high efficacy for symptoms like heavy bleeding—issues SWHR identifies as major burdens. In 2025, with SWHR’s push for collaborative research, UFE stands out for its ability to address fibroids in diverse populations, reducing the need for hysterectomies that disproportionately affect Black women.
The agenda’s integration with autoimmune and cardiometabolic priorities also resonates, as fibroids link to broader health issues like metabolic disorders—areas where UFE’s symptom relief can improve overall well-being. For women in Maryland, DC, and Virginia, Surgical Associates positions UFE as an SWHR-aligned treatment, offering quick recovery (1-2 weeks) and long-term benefits.
Schedule a screening or consultation at our Camp Springs, Waldorf, Washington D.C., Silver Spring, or Reston locations today. Call (240) 427-1630 or visit www.sacmd.com. Your journey to be Fibroid Free with UFE starts here!
Broader Implications for Trending Fibroid Advocacy in 2025
SWHR’s agenda fuels trending fibroid advocacy, including calls for federal funding and awareness campaigns. In July 2025, SWHR celebrated legislative packages aimed at advancing uterine health, such as dedicated research dollars for fibroids. This momentum encourages treatments like UFE, which reduce healthcare disparities and empower women through informed choices.
At sacmd.com, we participate in this advocacy by providing equitable access to UFE, helping bridge research gaps in real-world care.
Challenges and Calls to Action from SWHR
Despite progress, SWHR notes persistent gaps in fibroid research funding and representation. The 2025 agenda urges stakeholders to collaborate on innovative solutions, positioning UFE as a bridge between research and practice.
Patient Perspectives: Aligning with SWHR Priorities
Women at Surgical Associates often echo SWHR’s focus: “Knowing UFE aligns with top research gave me confidence—it’s transformed my uterine health.”
Align Your Care with SWHR’s Vision
SWHR’s 2025 agenda prioritizes uterine fibroids and embolization, like UFE, as essential for advancing women’s health. If you’re ready to benefit from this uterine health research in Maryland, DC, or Virginia, Surgical Associates and Dr. Albert Chun offer expert, agenda-aligned care. Schedule a screening or consultation at our Camp Springs, Waldorf, Washington D.C., Silver Spring, or Reston locations today. Call (240) 427-1630 or visit www.sacmd.com. Your journey to be Fibroid Free with UFE starts here!
Align your care with top research at sacmd.com.

Dr. Rahbar is an esteemed vascular surgeon at Surgical Associates, known for their exceptional contributions to the field of vascular surgery. As a board-certified vascular surgeon with over 20 years of invaluable experience, Dr. Rahbar is a respected authority in the medical community serving Reston, VA, Maryland & DC. His unwavering dedication to providing advanced care for patients with diseases of the arteries and veins has earned them a reputation for excellence. Dr. Rahbar’s work embodies a passion for precision and compassion, improving the lives of those they serve, one procedure at a time.